麻豆mv在线观看,国产a级淫片,国产高清在线精品一本大道

FDA Approvals Summary - July 2025 FDA Drug Approvals FDA approved several new drugs in July 2025, including treatments for phenylketonuria, chronic hand eczema, hereditary angioedema, EGFR-mutated lung cancer, and relapsed multiple myeloma, offering new hope for patients.
New Drug Approval Trends (2015-2024) by FDA, EMA, PMDA & Other Agencies Market Trend Trends in new drug approvals from 2015-2024 by six major regulatory agencies including FDA, EMA, PMDA, highlighting approval numbers, timelines, accelerated pathways, and patient experience data integration.
FDA Approvals Summary - June 2025 FDA Drug Approvals Explore FDA-approved new drugs from June 2025, including breakthroughs for hereditary angioedema, lung cancer, RSV, HIV prevention, bladder cancer, and rare diseases.
FDA Approvals Summary - April 2025 FDA Drug Approvals Discover the FDA's new drug approvals in April 2025, including treatments for IgAN, nasopharyngeal carcinoma, myasthenia gravis, and colorectal cancer. Learn about groundbreaking therapies like Vanrafia, Penpulimab-KCQX, and Imaavy.
FDA Layoffs Affect Drug Approvals, Forcing Pharma Companies to Exploit Loopholes FDA FDA layoffs delay drug approvals, forcing Daré Bioscience to use regulatory loopholes to launch a female-use sildenafil cream, raising safety and oversight concerns.
FDA Approvals Summary - March 2025 FDA Drug Approvals A summary of FDA drug approvals in March 2025, including new treatments for asthma, food allergies, osteoporosis, Prader-Willi syndrome, hemophilia, and more.
FDA Approves CtexliTM (chenodiol) for the Treatment of Rare Disease Cerebrotendinous Xanthomatosis FDA FDA approves CtexliTM (chenodiol) for the treatment of Cerebrotendinous Xanthomatosis (CTX), a rare genetic disorder affecting bile acid metabolism. CtexliTM is the first FDA-approved drug for CTX, offering a new treatment option for patients.
FDA Approved Summay - Januaray 2025 FDA Drug Approvals Explore FDA drug approvals from January 2025, including treatments for Crohn's disease, colorectal cancer, Alzheimer's, migraine, and more. Key approvals from Eli Lilly, Amgen, AstraZeneca, and others reshape patient care options.
FDA 2025 Q1 Approval Overview (II) FDA Drug Approvals Explore the FDA 2025 Q1 approval overview, featuring groundbreaking treatments like Vimseltinib for TGCT, Mirdametinib for NF1-PN, and innovative therapies in oncology, immunology, and more.
FDA 2025 Q1 Approval Overview (I) FDA Drug Approvals The FDA's 2025 Q1 approval pipeline includes promising treatments for diabetes, cancer, and central nervous system disorders. Key candidates include Ozempic for kidney disease, Subvenite for epilepsy, and TX05, a HER2-targeted cancer biosimilar.

<Pre12 Next >

Articles Archives

Hot Articles

All Categories

Agri & Industry Cosmetic Laboratory Pharmaceutical Food

永久免费毛片_亚洲成人看片_亚洲春色另类_亚洲综合免费视频_最新高清无码专区_午夜影院a